What are the public health effects of direct-to-consumer drug advertising?

Elizabeth A. Almasi, Randall S. Stafford, Richard L Kravitz, Peter R. Mansfield

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background to the debate: Only two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban [1]. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits.

Original languageEnglish (US)
Pages (from-to)284-288
Number of pages5
JournalPLoS Medicine
Volume3
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Public health
Marketing
Public Health
New Zealand
Pharmaceutical Preparations
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Insurance Benefits
Developed Countries
Myocardial Ischemia
Prescriptions
Health
Costs and Cost Analysis
Planning
Direct-to-Consumer Advertising
Costs

ASJC Scopus subject areas

  • Medicine(all)

Cite this

What are the public health effects of direct-to-consumer drug advertising? / Almasi, Elizabeth A.; Stafford, Randall S.; Kravitz, Richard L; Mansfield, Peter R.

In: PLoS Medicine, Vol. 3, No. 3, 03.2006, p. 284-288.

Research output: Contribution to journalArticle

Almasi, Elizabeth A. ; Stafford, Randall S. ; Kravitz, Richard L ; Mansfield, Peter R. / What are the public health effects of direct-to-consumer drug advertising?. In: PLoS Medicine. 2006 ; Vol. 3, No. 3. pp. 284-288.
@article{518580ca3d9846d396ac4c097fae40b3,
title = "What are the public health effects of direct-to-consumer drug advertising?",
abstract = "Background to the debate: Only two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban [1]. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits.",
author = "Almasi, {Elizabeth A.} and Stafford, {Randall S.} and Kravitz, {Richard L} and Mansfield, {Peter R.}",
year = "2006",
month = "3",
doi = "10.1371/journal.pmed.0030145",
language = "English (US)",
volume = "3",
pages = "284--288",
journal = "PLoS Medicine",
issn = "1549-1277",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - What are the public health effects of direct-to-consumer drug advertising?

AU - Almasi, Elizabeth A.

AU - Stafford, Randall S.

AU - Kravitz, Richard L

AU - Mansfield, Peter R.

PY - 2006/3

Y1 - 2006/3

N2 - Background to the debate: Only two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban [1]. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits.

AB - Background to the debate: Only two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban [1]. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits.

UR - http://www.scopus.com/inward/record.url?scp=33645350136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645350136&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.0030145

DO - 10.1371/journal.pmed.0030145

M3 - Article

C2 - 16563041

AN - SCOPUS:33645350136

VL - 3

SP - 284

EP - 288

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 3

ER -